Equity · Healthcare
Boston Scientific Corporation (BSX) perpetual futures
BSX perpetual futures on 2 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade BSXUSDT.
Boston Scientific is a global medical technology company that designs and sells innovative medical devices for interventional specialties, including cardiology, rhythm management, neurology, and surgery.
Price chart
Use the left and right arrow keys to inspect points on the chart.
Trading data
Perpetual market activity
2/3 live markets
Trading data
Perpetual market activity
Spot performance
Venue matrix
3 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kNo sufficient depth · 0 of 2 venues absorb $10k
No fresh book data: Gate.io, MEXC
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
BSXTightest spread
BSXHighest volume
BSXFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $53.77 |
| 12-month target range (low – high) | $44 – $71 |
| Ratings in the provider's consensus | 44 |
Price targets as of 2026-11-22
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 6 | 14 | 12 | 0 | 0 |
| Oct 2026 | 8 | 18 | 11 | 0 | 0 |
| Sep 2026 | 8 | 18 | 6 | 0 | 0 |
| Aug 2026 | 8 | 19 | 5 | 0 | 0 |
| Jul 2026 | 8 | 20 | 5 | 0 | 0 |
| Jun 2026 | 7 | 21 | 4 | 0 | 0 |
| May 2026 | 9 | 23 | 4 | 0 | 0 |
| Apr 2026 | 10 | 24 | 2 | 0 | 0 |
| Mar 2026 | 10 | 25 | 0 | 0 | 0 |
| Feb 2026 | 9 | 26 | 1 | 0 | 0 |
| Jan 2026 | 7 | 26 | 2 | 0 | 0 |
| Dec 2025 | 7 | 25 | 2 | 0 | 0 |
Ownership
Institutional · 2026-Q3Reference market activity
BSX-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25CEO Mahoney reported two gift transactions of Boston Scientific common stock totaling 252,241 shares at $0.00 on 2026-11-04.
On 2026-11-01, officer Miriam O'Sullivan exercised 3,871 restricted stock units into 3,871 common shares (M-Exempt) and had 1,872 shares withheld for taxes at $41.98 (F-InKind), leaving 19,565 shares owned.
On Sep 2, 2026, the SVO of Global Operations converted 1,171 RSUs into common stock; 567 shares were withheld for taxes at $48.37, leaving a balance of 7,892 shares.
Susan E. Morano, a director of Boston Scientific, acquired 2,040 common shares in an open-market purchase at $49.2195 per share on August 25, 2026. She now owns 13,784 shares.
Officer Emily Woodworth acquired 2,930 common shares via discretionary transaction at $51.19 per share on 2026-08-11.
On Aug 10, 2026, CFO Jonathan Monson acquired 9,908 common shares at $50.46 each in a discretionary transaction, now holding 9,908 shares.
Director David C. Habiger bought 2,100 common shares of Boston Scientific at $47.589 each on 2026-08-05, increasing his holdings to 17,160 shares.
Director David C. Habiger bought 1,182 shares of Boston Scientific common stock on the open market on Aug 3-4, 2026, at prices between $48.07 and $48.59, bringing his total ownership to 15,060 shares.
Michael F. Mahoney, Chairman, President & CEO of Boston Scientific, purchased 186,240 shares of common stock on the open market at $48.3323 per share, and separately acquired 22,119 shares at $48.43 per share.
Director Edward J. Ludwig bought 5,000 shares of Boston Scientific common stock on the open market at $45.48 per share, bringing his total ownership to 30,359 shares.
Joseph Michael Fitzgerald, EVP & Group President Cardiology, acquired 64,198 shares of Boston Scientific common stock at $46.73 per share on 2026-07-31, resulting in 64,198 shares owned afterward.
CFO Jonathan Monson converted 2,087 RSUs into 2,087 common shares, then had 1,010 shares withheld at $43.06 to cover taxes, leaving 39,063 shares owned.
Michael F. Mahoney, Chairman, President & CEO of Boston Scientific, gifted 386,755 shares of common stock on 2026-05-28, leaving 0 shares owned afterward.
Director Cheryl Pegus purchased 1,770 shares of Boston Scientific common stock on the open market at $56.49 per share, bringing her ownership to 1,770 shares.
Director Edward J. Ludwig purchased 3,580 shares of Boston Scientific common stock on the open market at $56.68 per share, bringing his ownership to 25,359 shares.
Director David C. Habiger bought 2,250 shares of Boston Scientific common stock on the open market at $55.9195 per share on May 20, 2026, leaving 13,878 shares owned.
Filings
58 · Latest SEC filingsCEO Mahoney reported two gift transactions of Boston Scientific common stock totaling 252,241 shares at $0.00 on 2026-11-04.
On 2026-11-01, officer Miriam O'Sullivan exercised 3,871 restricted stock units into 3,871 common shares (M-Exempt) and had 1,872 shares withheld for taxes at $41.98 (F-InKind), leaving 19,565 shares owned.
On Sep 2, 2026, the SVO of Global Operations converted 1,171 RSUs into common stock; 567 shares were withheld for taxes at $48.37, leaving a balance of 7,892 shares.
Susan E. Morano, a director of Boston Scientific, acquired 2,040 common shares in an open-market purchase at $49.2195 per share on August 25, 2026. She now owns 13,784 shares.
Officer Emily Woodworth acquired 2,930 common shares via discretionary transaction at $51.19 per share on 2026-08-11.
On Aug 10, 2026, CFO Jonathan Monson acquired 9,908 common shares at $50.46 each in a discretionary transaction, now holding 9,908 shares.
Director David C. Habiger bought 2,100 common shares of Boston Scientific at $47.589 each on 2026-08-05, increasing his holdings to 17,160 shares.
Director David C. Habiger bought 1,182 shares of Boston Scientific common stock on the open market on Aug 3-4, 2026, at prices between $48.07 and $48.59, bringing his total ownership to 15,060 shares.
Michael F. Mahoney, Chairman, President & CEO of Boston Scientific, purchased 186,240 shares of common stock on the open market at $48.3323 per share, and separately acquired 22,119 shares at $48.43 per share.
Director Edward J. Ludwig bought 5,000 shares of Boston Scientific common stock on the open market at $45.48 per share, bringing his total ownership to 30,359 shares.
Joseph Michael Fitzgerald, EVP & Group President Cardiology, acquired 64,198 shares of Boston Scientific common stock at $46.73 per share on 2026-07-31, resulting in 64,198 shares owned afterward.
CFO Jonathan Monson converted 2,087 RSUs into 2,087 common shares, then had 1,010 shares withheld at $43.06 to cover taxes, leaving 39,063 shares owned.
Michael F. Mahoney, Chairman, President & CEO of Boston Scientific, gifted 386,755 shares of common stock on 2026-05-28, leaving 0 shares owned afterward.
Director David C. Habiger bought 2,250 shares of Boston Scientific common stock on the open market at $55.9195 per share on May 20, 2026, leaving 13,878 shares owned.
Director Edward J. Ludwig purchased 3,580 shares of Boston Scientific common stock on the open market at $56.68 per share, bringing his ownership to 25,359 shares.
Director Cheryl Pegus purchased 1,770 shares of Boston Scientific common stock on the open market at $56.49 per share, bringing her ownership to 1,770 shares.
Jessica L. Mega, director, was awarded 3,800 shares of Boston Scientific common stock on 2026-05-07 as compensation, bringing her total ownership to 12,035 shares.
David C. Habiger, a director, was awarded 3,800 shares of Boston Scientific common stock on 2026-05-07 at no cost, bringing his total ownership to 9,428 shares.
Boston Scientific director Susan E. Morano received 5,081 common shares in two award grants on 2026-05-07. No open-market purchases or sales were reported.
Boston Scientific director Edward J. Ludwig was awarded 3,800 shares of common stock (a compensation grant, not an open-market purchase) on 2026-05-07, bringing his total holdings to 21,779 shares.
Director Christophe Pierre Weber received 2,907 common shares and 2,660 deferred stock units as compensation awards from Boston Scientific on May 7, 2026, at $0.00 per share.
Boston Scientific director Pegus Cheryl received 5,081 deferred stock units in two award grants on May 7, 2026, at $0.00 per unit. Awards are compensation, not open-market purchases.
Director Cathy R. Smith received two grants of deferred stock units totaling 6,009 units on 2026-05-07, as compensation rather than a purchase. She held 6,888 and 4,679 units, respectively, after the two transactions.
Director David S. Wichmann received a grant/award of 3,800 Boston Scientific common shares on 2026-05-07, bringing his total ownership to 45,382 shares.
Director Zane Ellen M was awarded 3,800 shares of Boston Scientific common stock on 2026-05-07 as compensation, bringing her total holdings to 27,934 shares.
O'Connor converted 1,802 RSUs into 1,802 Boston Scientific common shares, then had 872 shares withheld to cover taxes at $56.50 each, leaving 7,024 shares owned.
Arthur Butcher converted 2,102 RSUs into 2,102 Boston Scientific common shares, then 1,007 shares were withheld to cover taxes at $56.50 per share.
Transcripts
Earnings callsFY2026 Q22026-07-29
Earnings calls
AI summary
mixedBoston Scientific reported solid Q2 2026 results with 7% organic revenue growth and $0.86 adjusted EPS, exceeding guidance. However, the company significantly reduced full-year 2026 guidance to 5-6% organic revenue growth and $3.28-$3.32 adjusted EPS, citing unexpected market dynamics in two key areas: WATCHMAN left atrial appendage closure device faced a sharp U.S. market slowdown driven by recent clinical evidence impacting referral patterns, with global growth now expected flat to low-single digits and second-half declines of mid- to high-single digits; and Electrophysiology experienced greater-than-anticipated competitive share movement in the U.S., with PFA now representing approximately 80% of the AFib market. The company expects limited EPS growth in 2027 but anticipates meaningful improvement in 2028 supported by new product launches across its Interventional Cardiology, Vascular, and EP portfolios, including entry into the IVL and ICE markets, renal denervation, and the pending Penumbra acquisition. Management announced a $500 million restructuring program targeting run-rate savings by end of 2029 to drive cost efficiencies while reinvesting in high-growth opportunities.
Key takeaways
- Q2 2026 organic revenue grew 7%, exceeding the 5-7% guidance range, with strong performance in Interventional Cardiology, Endoscopy, and Neuromodulation growing double digits
- WATCHMAN U.S. market slowed sharply due to compounding clinical evidence impacting referral patterns, with stand-alone procedures declining mid-teens while concomitant procedures grew over 60% but facing high 2025 comparisons
- Electrophysiology grew 9% overall with 3% U.S. growth and 23% international growth, but U.S. market share declined due to PFA market accelerating to 80% penetration and increased competitive pressures
- Company projects challenging 2027 with WATCHMAN and EP pressures expected to persist, but expects return to strong growth in 2028 supported by seven meaningful product launches exceeding $25 billion TAM including IVL, hypertension therapy, Penumbra, ICE imaging, and next-generation EP catheters
Financial highlights
- Q2 2026 consolidated revenue of $5.442 billion grew 7.5% reported and 7.0% organically, with 50 basis point FX tailwind
- Q2 adjusted EPS of $0.86 grew 15% versus prior year, exceeding guidance range of $0.82-$0.84, primarily driven by favorable discrete tax items
- Q2 adjusted gross margin of 70.3% represented 80 basis point expansion versus prior year; adjusted operating margin of 28.4% expanded 70 basis points
- Full-year 2026 guidance: organic revenue growth 5-6%, adjusted EPS $3.28-$3.32 (7-8% growth), adjusted gross margin expected below prior year due to unfavorable product mix and continued supply chain investments, operating margin expansion of 0-25 basis points
Guidance
- Full-year 2026 organic revenue growth of 5-6% with Q3 guidance of 3-5% organic growth
- Full-year 2026 adjusted EPS of $3.28-$3.32 representing 7-8% growth; Q3 adjusted EPS guidance of $0.80-$0.82
- Global WATCHMAN growth expected flat to low-single digits with second-half declines mid- to high-single digits; U.S. flat full-year growth with Q3 mid-single-digit sequential decline
- Global Electrophysiology expected flat growth in second half 2026; U.S. flat to low-single-digit full-year growth with international growth approximately 20%; improvement anticipated in second half 2027 with new product launches
Q&A themes
- WATCHMAN market dynamics driven by clinical evidence integration impacting referral patterns, with stand-alone procedure weakness offset by growing concomitant procedure adoption; company implementing physician education, commercial expansion, and direct-to-patient investments to reaccelerate growth
- Electrophysiology experiencing U.S. market share pressure despite portfolio strength, with PFA technology reaching 80% market penetration limiting competitive positioning; company confident in recovery through FARAWAVE Ultra launch in late 2027 and ICE market entry
- 2027 outlook expected to show limited EPS growth with continued WATCHMAN and EP pressures extending into year, improving in 2028 as new platforms launch including IVL, renal denervation, Penumbra, ICE, and next-generation EP catheters
- Company restructuring and cost reduction program designed to protect high-growth markets while delivering $500 million in run-rate savings and position for return to double-digit EPS growth in 2028 and beyond
Risks
- WATCHMAN U.S. market experienced sharper-than-expected slowdown driven by clinical evidence regarding stroke risk in AF patients published over past nine months, with no assumed improvement in 2027 guidance despite company mitigation efforts
- Electrophysiology competitive dynamics worsened as PFA market accelerated to 80% of AFib market, limiting Boston Scientific's ability to offset competitive pressures despite continuing PFA leadership and strong international performance
- 2027 expected to deliver limited EPS growth and operating margin pressure from continued softness in WATCHMAN and Electrophysiology combined with anticipated dilution from Penumbra acquisition, delaying return to strong financial performance until 2028
FY2026 Q12026-04-22
Earnings calls
AI summary
mixedBoston Scientific delivered Q1 2026 organic revenue growth of 9.4% and adjusted EPS of $0.80, meeting guidance, but significantly reduced full-year 2026 organic growth guidance from prior expectations to 6.5%-8% due to pressures in electrophysiology (mid-single digit U.S. growth vs. prior market growth expectations), WATCHMAN (mid-teens global vs. prior 20%+ growth), and Urology (low to mid-single digits). The company maintained confidence in long-term performance, citing an 8% WAMGR market, strong international growth, and an impressive pipeline of upcoming product launches.
Key takeaways
- Q1 organic revenue growth of 9.4% and adjusted EPS of $0.80 achieved high end of guidance; Q1 adjusted operating margin was 28%
- Full-year 2026 organic growth guidance reduced to 6.5%-8% (from prior 8.5%-10% range) driven by EP, WATCHMAN, and Urology underperformance
- Penumbra acquisition expected to close in H2 2026; $2 billion share repurchase planned for Q2 subject to market conditions
- Company expects margin expansion of 50-75 basis points and adjusted EPS growth of 9%-11% for full-year 2026 despite revenue headwinds
Financial highlights
- Q1 2026 organic revenue growth: 9.4%; reported revenue growth: 11.6% (includes 220 bps FX tailwind)
- Q1 adjusted EPS: $0.80, +6% vs. 2025; full-year adjusted EPS guidance: $3.34-$3.41 (+9%-11%)
- Q1 adjusted gross margin: 70.5% (-100 bps vs. Q1 2025); full-year adjusted operating margin expansion expected: 50-75 bps
- Full-year 2026 free cash flow expected: ~$4 billion; gross debt leverage ratio: 1.8x as of March 31, 2026
Guidance
- Full-year 2026 organic revenue growth: 6.5%-8% (revised down); Q2 2026 organic growth: 5.0%-7.0%
- Full-year 2026 adjusted EPS: $3.34-$3.41 (+9%-11%); Q2 adjusted EPS: $0.82-$0.84
- Global WATCHMAN growth (full year 2026): mid-teens; U.S. WATCHMAN: low to mid-teens
- Global EP growth (full year 2026): ~10%; U.S. EP: mid-single digit; International EP: +20%
Q&A themes
- WATCHMAN headwinds driven by hospital workflow prioritization, concomitant adoption acceleration, and stand-alone procedure deceleration; company plans increased commercial and marketing investments to support growth
- EP share erosion reflects increased competition from Medtronic, J&J, and Abbott; confidence maintained in maintaining PFA market leadership through product innovation pipeline including FARAWAVE Ultra (H1 2027) and FANAFLEX (U.S. launch 2028)
- Urology challenges primarily due to stone management VBP impact in China and sacral neuromodulation commercial disruption; company hired ~100 new sales/clinical reps; expects improvement with product launches in 2026 and Valencia Technologies acquisition (closed April)
- 2027 expected to show improvement with easier comps, key product launches, and resolution of transient supply chain issues; company reaffirms confidence in achieving 8% WAMGR and maintaining leadership position long-term
Risks
- Unanticipated market headwinds in EP, WATCHMAN, and Urology resulted in significant full-year guidance reduction; WATCHMAN facing stand-alone procedure deceleration and hospital capacity constraints
- Gross margin pressure from tariffs, inventory charges related to POLARx discontinuation, and lower-than-expected product mix benefit; company now expects full-year adjusted gross margin slightly below 2025
- Penumbra acquisition contingent on shareholder vote (May 6) and remaining regulatory clearances; deal funding approach under shareholder scrutiny given revised stock performance
FY2025 Q42026-02-04
Earnings calls
AI summary
positiveBoston Scientific achieved over $20 billion in sales for 2025 with mid-teens organic growth driven by strength in EP (35% organic growth), WATCHMAN (29% growth), and broad-based performance across business units. The company expects 2026 organic revenue growth of 10-11% and adjusted EPS growth of 12-14%, with additional scale from pending acquisitions of Valencia Technologies and Penumbra expected to close in 2026.
Key takeaways
- Q4 2025 organic revenue growth of 13% and full-year organic growth of 16% exceeded guidance; adjusted EPS grew 22% for the full year with Q4 EPS of $0.80
- EP grew 35% organically in Q4 (73% full year), with approximately 70% PFA market penetration in U.S.; WATCHMAN delivered 29% Q4 growth with concomitant procedures now exceeding 25,000 patients treated
- Six of eight business units grew faster than market in 2025; 2026 guidance anticipates 10-11% organic growth with 12-14% EPS growth and 50-75 basis points of operating margin expansion
- Pending acquisitions of Valencia Technologies and Penumbra announced to strengthen urology and cardiovascular portfolios; CHAMPION WATCHMAN trial and multiple clinical studies expected to report in 2026
Financial highlights
- Full-year 2025 organic revenue growth of 15.8%; Q4 operational revenue growth of 14.3% with $5.286 billion in total revenue
- Full-year adjusted EPS of $3.06, growing 22%; Q4 adjusted EPS of $0.80, growing 15%, both exceeding guidance ranges
- Full-year adjusted gross margin of 70.6% (30 basis point expansion); adjusted operating margin of 28% (100 basis point expansion)
- 2026 guidance: organic revenue growth 10-11%, adjusted EPS $3.43-$3.49 (12-14% growth), free cash flow approximately $4.2 billion
Guidance
- Q1 2026 organic revenue growth guidance of 8.5-10% (includes 150 basis point headwind from ACURATE discontinuation and AXIOS product removal)
- Full year 2026 organic revenue growth guidance of 10-11% and adjusted EPS growth of 12-14% ($3.43-$3.49 per share)
- Adjusted operating margin expansion of 50-75 basis points in 2026, progressing toward long-range plan goal of 150 basis points
- Long-range plan targets of 10%-plus organic revenue growth, 150 basis points of operating margin expansion, and double-digit EPS growth through 2028
Q&A themes
- EP market growth estimated at 18-20% in Q4 2025 (lower than some competitor claims of 25%); management expects 15% EP market growth in 2026 with Boston Scientific outpacing market despite anticipated share normalization
- WATCHMAN not impacted by recent trial results (CLOSURE-AF, OCEAN); CHAMPION trial acceptance as late breaker at ACC could expand indicated patient population from 5 million to 20 million globally if positive
- Capacity constraints in EP labs noted with growing waitlists; management expects ASC buildout and continued procedure efficiency gains to drive future growth without exceeding 20% market growth
- Neuromodulation, Urology, Endoscopy, and CRM expected to show stronger performance in 2026 versus 2025; diversification across eight business units provides confidence in overall company guidance
Risks
- Urology and Endoscopy faced headwinds in 2025; Endoscopy product removal of certain AXIOS device sizes expected to impact first-half 2026 growth, with full return anticipated by mid-year
- EP market competitive dynamics with new entrants launching competing products; company anticipates share normalization but maintains confidence in market leadership position
- Pending Penumbra acquisition subject to customary closing conditions and regulatory approval; Valencia Technologies acquisition expected to close in first half of 2026
FY2025 Q32025-10-22
Earnings calls
AI summary
positiveBoston Scientific delivered Q3 operational sales growth of 19% and organic growth of 15%, surpassing its 12-14% guidance range, led by exceptional performance in electrophysiology (up 63%) and WATCHMAN (up 35%). The company raised full-year organic revenue growth guidance to approximately 15.5% and full-year adjusted EPS guidance to $3.02-$3.04, representing 20-21% growth. Management confirmed confidence in sustained above-market growth across the portfolio, with particular strength in the U.S. market, offset by transient headwinds in Europe from the ACURATE valve discontinuation and ERP system implementation issues.
Key takeaways
- Q3 organic revenue growth of 15% exceeded guidance; full-year raised to 15.5% organic growth with adjusted EPS guidance raised to $3.02-$3.04
- EP delivered exceptional 63% growth, with FARAPULSE treating over 500,000 patients; WATCHMAN grew 35% with concomitant procedures reaching 25% penetration and pathway to potentially double by 2028
- U.S. grew 27% operationally, while EMEA declined 2% due to $50M ACURATE valve discontinuation and $30M ERP backorder; Asia Pac grew 17% with China achieving mid-teens growth despite VBP pressures
- Company signed agreement to acquire Nalu Medical for peripheral nerve pain adjacency and closed Elutia BioEnvelope acquisition for CRM portfolio; targeting 10%+ organic growth and 50 bps annual margin expansion through 2028
Financial highlights
- Q3 organic revenue growth of 15.3% versus 12-14% guidance; adjusted EPS of $0.75 grew 19% versus $0.70-$0.72 guidance
- Q3 adjusted gross margin of 71%, up 60 basis points year-over-year from favorable product mix; full-year adjusted operating margin expanded 100 basis points despite $100M tariff headwind
- Full-year 2025 organic growth guided to 15.5%; Q4 organic growth guided to 11-13%; full-year free cash flow expected at approximately $3.5 billion
- Full-year adjusted operating margin expected to expand 100 basis points at high end of prior 75-100 basis point range; adjusted tax rate targeted at 12.5%
Guidance
- Full-year 2025 organic revenue growth raised to approximately 15.5% versus prior guidance; Q4 organic growth guided to 11-13%
- Full-year adjusted EPS raised to $3.02-$3.04, representing 20-21% growth; Q4 adjusted EPS guided to $0.77-$0.79
- WATCHMAN expected to grow at approximately 20% CAGR over long-range plan; global PFA penetration expected to reach 50% by end of 2025 and grow to approximately 80% by 2028
- 2026-2028 targets: 10%+ average organic revenue growth, approximately 50 basis points annual adjusted operating margin expansion, double-digit adjusted EPS growth, and 70-80% annual free cash flow conversion
Q&A themes
- WATCHMAN and concomitant AF ablation procedures represent major growth driver with 20% market CAGR expected over long-range plan; CHAMPION trial data expected first half 2026 and WATCHMAN Elite launch expected late 2027 or early 2028
- China business achieving mid-teens growth despite VBP headwinds through innovation, WATCHMAN FLX Pro launch, and EP expansion; management expects double-digit growth continuation across long-range plan
- No evidence of procedural pull-forward observed in Q3; management expects consistent procedural demand to continue
- FARAPULSE de novo persistent AF ablation showing single-digit redo rates with strong outcomes; FARAPOINT catheter for complex redos expected end of 2025; OPTIMIZE trial will study OPAL and Cortex AI algorithm integration
Risks
- EMEA region faced transient headwinds including $50M ACURATE valve discontinuation in May 2025 and $30M ERP implementation backorder at Kerkrade facility; backorder expected to improve through Q4 but team still working to return to acceptable levels
- Axonics SNM business continues to underperform expectations due to unplanned commercial disruption; company focused on improving commercial execution, though remains enthusiastic about market opportunity and expects improvement in 2026
- Tariff headwind of approximately $100M for full-year 2025; continued tariff impact expected in 2026 with annualization effects as headwind to gross margin expansion
FY2025 Q22025-07-23
Earnings calls
AI summary
positiveBoston Scientific exceeded Q2 expectations with 17% organic revenue growth and $0.75 adjusted EPS (23% growth), led by exceptional cardiovascular segment performance including 94% EP growth from FARAPULSE and 28% WATCHMAN growth. The company raised full-year 2025 organic growth guidance to 14-15% from 12-14% and now expects $2.95-$2.99 adjusted EPS representing 18-19% growth, reflecting strong momentum across all regions despite ACURATE discontinuation charges.
Key takeaways
- Q2 organic revenue grew 17%, well above guidance of 13-15%, with adjusted EPS of $0.75 growing 23%
- Electrophysiology surged 94% driven by FARAPULSE adoption with over 15,000 patients in Japan and mid-teens sequential growth; WATCHMAN grew 28% with 60% of EP implanters now performing concomitant procedures
- Full-year organic growth guidance raised to 14-15% (from 12-14%) and adjusted EPS guidance to $2.95-$2.99 representing 18-19% growth
- U.S. operational growth of 31% led by cardiovascular portfolio; Asia-Pacific grew 15% with Japan high-teens growth and China returning to mid-teens growth
- Acquired SoniVie and Intera Medical to strengthen interventional cardiology and interventional oncology portfolios; free cash flow guidance of $3.5 billion for full year
Financial highlights
- Q2 operational revenue growth of 22%, organic growth of 17%, exceeding guidance range of 13-15%
- Q2 adjusted EPS of $0.75, up 23% versus prior year, exceeding guidance of $0.71-$0.73
- Full-year 2025 organic revenue growth guidance of 14-15% (raised from 12-14%); operational growth of 17.5-18.5%
- Full-year adjusted EPS guidance of $2.95-$2.99 representing 18-19% growth; Q3 EPS guidance of $0.70-$0.72
Guidance
- Full-year 2025 organic revenue growth: 14-15% (raised from 12-14%); operational growth 17.5-18.5%
- Full-year 2025 adjusted EPS: $2.95-$2.99, representing 18-19% growth; Q3 adjusted EPS: $0.70-$0.72
- Q3 2025 organic revenue growth: 12-14%; operational growth 16.5-18.5%
- Full-year adjusted operating margin expansion: 75-100 basis points; full-year adjusted gross margin expected to be roughly flat versus 2024
Q&A themes
- WATCHMAN growth driven by OPTION data, concomitant procedure adoption (60% of EP implanters), and FLX Pro approvals; expected 20%+ category growth; CHAMPION trial data expected first half 2026
- FARAPULSE market expansion through persistent AFib indication expansion, third-generation device iterations, mapping system adoption, and geographic growth in Japan (clear market leader) and early-stage China rollout
- ASC impact seen as net positive despite potential lower concomitant procedure rates; gradual transition expected starting with simpler de novo paroxysmal AFib cases in states without CONs (40% of market)
- SoniVie acquisition positions Boston Scientific well in ultrasound renal denervation market with expected approval timing not far behind competitors; potential multi-billion dollar market opportunity over time
Risks
- ACURATE valve discontinuation resulted in ~$100 million inventory and reserves charges impacting adjusted gross margin by 100 bps and creating ~800 bps headwind to ICTx growth in second half 2025
- Proposed Medicare physician fee cut of 16% for LAA procedures could impact reimbursement; competitive intensity in EP market from established competitors with existing mapping infrastructure
- Tariff headwind of approximately $100 million expected in full year 2025 (predominantly second half); supply chain constraints in urology business expected to improve in second half but create near-term growth pressure
FY2025 Q12025-04-23
Earnings calls
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.- Boston Scientific Cuts View Again After Cyberattack, Other Challenges
- Boston Scientific Restores Key Operations After Cyberattack
- Boston Scientific Won't Meet Guidance Due to Cyberattack
- Boston Scientific says cyberattack likely to hurt 2026 sales, profit
- Boston Scientific hit by cyberattack, global operations affected
Company data
Company intelligence
Updated: Nov 22, 2026, 10:53 AM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Medical - Devices
- Chief executive
- Michael F. Mahoney
- Employees
- 59,000
- IPO date
- May 19, 1992
- Country
- US
- Exchange
- New York Stock Exchange
Rating factors
- Return on equityi
- 4/5
- Return on assetsi
- 5/5
- Debt to equityi
- 2/5
- Price to earningsi
- 2/5
- Price to booki
- 3/5
Company press releases
Congressional disclosures
Senate
House
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VTI | 0.1% | 47.2M |
| VOO | 0.11% | 39.5M |
| VPMAX | 1.37% | 30.9M |
| FXAIX | 0.11% | 20.7M |
| IVV | 0.1% | 18.5M |
| SPY | 0.1% | 17.4M |
| S5SD.L | 0.16% | 11.6M |
| VGHAX | 1.24% | 11.3M |
| XLV | 1.03% | 10.1M |
| VECP.S | 0.19% | 10M |
| VUG | 0.11% | 9.1M |
| VHCAX | 1.15% | 8.8M |
Analyst track record
How the analysts covering BSX have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 248 | 644 |
| Analysts | 32 | 36 |
| Buy / hold / sell | 229 / 19 / 0 | 605 / 39 / 0 |
| Upgrades / downgrades / initiations | 1 / 8 / 3 | 4 / 10 / 6 |
| Price targets hit / missed | 0 / 230 (0%) | 0 / 590 (0%) |
| Avg. return after a rating (TipRanks) | -44.1% | -51.1% |
| Best / worst call | -2.3% / -68.4% | -2.3% / -69.3% |
After buy calls on this stock: median 21-day move +1.4% vs S&P 500 -1.8% (n = 640)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Patrick WoodUBS71% hit rate on this stock · 17 targets measuredBuytarget $57.00Oct 29, 2026
- Matthew O'BrienPiper Sandler69% hit rate on this stock · 16 targets measuredBuytarget $60.00Oct 14, 2026
- William PlovanicCanaccord Genuity68% hit rate on this stock · 19 targets measuredBuytarget $48.00Nov 3, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 19, 2026 | Joanne WuenschCitiNov 19, 2026 | HoldReiterated | $44.00↗ | article ↗ |
| Nov 3, 2026 | William PlovanicCanaccord GenuityNov 3, 2026 | BuyMaintained | $48.00↗ | article ↗ |
| Nov 2, 2026 | David ToungArgus ResearchNov 2, 2026 | HoldMaintained | –↗ | article ↗ |
| Nov 2, 2026 | Robbie MarcusJ.P. MorganNov 2, 2026 | HoldMaintained | –↗ | article ↗ |
| Oct 30, 2026 | Travis SteedBank of America SecuritiesOct 30, 2026 | BuyReiterated | $54.00↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 20, 2026 · 248 ratings
Frequently asked questions
Where can I trade BSX perpetual futures?
Boston Scientific Corporation (BSX) perpetual futures trade on 2 crypto venues, including MEXC, Gate.io. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade BSX around the clock?
Yes. Unlike the underlying stock, BSX perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on BSX perpetuals?
Right now the BSX perp funding rate is +11.0% annualized (venue median), ranging from 0.0% to +21.9% across 2 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the BSX perp price compare to the Boston Scientific Corporation stock?
The venue-median BSX perp mark is $42.2 versus a reference stock price of $42, a basis of +0.5%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a BSX perpetual future?
A BSX perpetual is a derivative that tracks the price of Boston Scientific Corporation with no expiry date. It lets you take long or short exposure to Boston Scientific Corporation on crypto venues, around the clock.
What is BSXUSDT perpetual?
BSXUSDT is the symbol most crypto exchanges use for the Boston Scientific Corporation perpetual settled in USDT (Tether). It tracks the BSX share price through an index, trades 24/7 with leverage and never expires.
MEXC
Gate.io
BingX